NCT07453225Not yet recruitingPhase 1/2
Empirical Radioactive Iodine Therapy in DTC
Efficacy of Empirical Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma Patients With Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) Syndrome
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
The aim of the study is assessment the efficacy of empiric RAI therapy in DTC patients with elevated thyroglobulin levels and negative iodine scintigraphy.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 25 Feb 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Apr 2028
- Lead sponsor
- Assiut University
- Diseases
- Thyroid cancer
- NCT number
- NCT07453225
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 100
- From 1 Apr 2026 to the primary completion date, 1 Apr 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Undifferentiated thyroid cancer.
- Patients with evidence of structural disease.
Age
- Patients less than 18 years old.
Who the study is looking for
- This study will include adult patients with pathologically proved DTC who underwent total thyroidectomy and received RAI therapy presented to our nuclear medicine unit with evidence of persistent or recurrent biochemical disease during follow up.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.